drugset / Trial / NCT02969980
Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS
NaSingle-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the feasibility and efficacy of post-transplantation cyclophosphamide with myeloablative or reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS).
Timeline
- Start
- 2016-11
- Primary completion
- 2021-12-16
- Completion
- 2021-12-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |